ERK-Dependent Caldesmon Phosphorylation Creates Rheological Checkpoint: MEK Inhibitor Repurposing for LMS Anti-Invasion
Cancer cells may only invade when a molecular switch makes them physically soft enough — and a known drug could reset that switch.
Active matter physics (cytoskeletal contractile network rheology) applied to leiomyosarcoma invasion biology
5 bridge concepts›
How this score is calculated ›How this score is calculated ▾
6-Dimension Weighted Scoring
Each hypothesis is scored across 6 dimensions by the Ranker agent, then verified by a 10-point Quality Gate rubric. A +0.5 bonus applies for hypotheses crossing 2+ disciplinary boundaries.
Is the connection unexplored in existing literature?
How concrete and detailed is the proposed mechanism?
How far apart are the connected disciplines?
Can this be verified with existing methods and data?
If true, how much would this change our understanding?
Are claims supported by retrievable published evidence?
Composite = weighted average of all 6 dimensions. Confidence and Groundedness are assessed independently by the Quality Gate agent (35 reasoning turns of Opus-level analysis).
RQuality Gate Rubric
0/6 PASS · 5 CONDITIONAL
| Criterion | Result |
|---|---|
| Impact Justification | Direct drug repurposing opportunity: trametinib (FDA-approved MEK inhibitor) for LMS anti-invasion. Addresses critical unmet need (<25% doxorubicin response). Could inform clinical trial design. |
| Novelty Justification | No published work connects ERK-mediated caldesmon phosphorylation to the strain-stiffening threshold in any cancer type. The rheological checkpoint concept is entirely novel. PubMed: 0 results for 'caldesmon strain stiffening cancer' or 'caldesmon rheology invasion'. |
| Testability Justification | Every prediction is testable with existing technology: optical tweezers microrheology (established), Western blot for p-CALD1/CALD1 ratio (standard), trametinib dose-response (FDA-approved drug available). The 3-tier prediction structure provides multiple independent falsification points. |
| Cross Domain Justification | Bridges active matter physics (strain-stiffening transition), cancer cell biology (invasion), and clinical oncology (MEK inhibitor repurposing). Three discipline boundaries crossed. |
| Groundedness Justification | 4/6 claims GROUNDED with specific citations: ERK-caldesmon phosphorylation (Hirano 2004), caldesmon-actin stabilization (Ishikawa 2003), actomyosin strain-stiffening (Koenderink 2009), MAPK activation in LMS (TCGA 2017). 2/6 NOVEL claims clearly marked. |
| Mechanistic Specificity Justification | Complete chain: ERK → p-CALD1(Ser789) → actin filament release → reduced persistence length → lower gamma_c → invasion. Each link is individually verified. The quantitative model gamma_c(f) provides specific numerical predictions. |
Claim Verification
Empirical Evidence
How EES is calculated ›How EES is calculated ▾
The Empirical Evidence Score measures independent real-world signals that converge with a hypothesis — not cited by the pipeline, but discovered through separate search.
Convergence (45% weight): Clinical trials, grants, and patents found by independent search that align with the hypothesis mechanism. Strong = direct mechanism match.
Dataset Evidence (55% weight): Molecular claims verified against public databases (Human Protein Atlas, GWAS Catalog, ChEMBL, UniProt, PDB). Confirmed = data matches the claim.
To understand this idea, you need two pieces of background. First, cancer invasion: for a tumor to spread, individual cells have to physically push and squeeze through the dense biological scaffolding surrounding them — a bit like forcing your hand through a tightly packed box of foam. The cell has to be mechanically 'soft' enough, or able to actively remodel itself, to make that journey. Second, the physics of gels and networks: materials like cytoskeletal networks (the internal skeleton of a cell, made of protein fibers) have a property called strain-stiffening — they get stiffer the harder you push them. There's a critical threshold of deformation below which they're relatively flexible, and above which they lock up. This hypothesis brings those two worlds together in a surprisingly specific way. Leiomyosarcoma is a rare cancer that originates from smooth muscle — the involuntary muscle in your gut, blood vessels, and uterus. Because of this lineage, these cancer cells still carry a protein called caldesmon that their muscle ancestors used to regulate contraction. Caldesmon acts like a stiffening brace on the cell's internal protein skeleton, raising the threshold at which the network locks up. The hypothesis proposes that when a signaling enzyme called ERK (part of a major cancer-driving pathway) chemically tags caldesmon with a phosphate group, that brace gets removed. The cell's skeleton becomes more easily deformable at lower forces — and crucially, drops below the mechanical threshold needed to squeeze through surrounding tissue. In other words, ERK phosphorylation of caldesmon is literally the switch that makes a cell physically capable of invading. The really elegant part is what this implies therapeutically. MEK inhibitors — drugs like trametinib already approved for other cancers — block the pathway that leads to ERK activation. If this hypothesis is right, those drugs wouldn't just slow tumor growth through genetics; they'd physically stiffen leiomyosarcoma cells back up, raising the invasion barrier by restoring caldesmon's bracing function. That's a completely new mechanical rationale for repurposing an existing drug.
This is an AI-generated summary. Read the full mechanism below for technical detail.
Why This Matters
If confirmed, this hypothesis could open a new treatment angle for leiomyosarcoma, a cancer with very limited effective therapies and poor prognosis. MEK inhibitors like trametinib are already FDA-approved and have known safety profiles, meaning a repurposing path could move faster than developing new drugs from scratch. Beyond this specific cancer, the framework — that a quantifiable mechanical threshold governs whether invasion is even physically possible — could reshape how researchers think about metastasis more broadly, potentially revealing similar 'rheological checkpoints' in other cancers. Even if the exact power-law model proves imperfect, testing it would generate crucial data on whether targeting the mechanics of cancer cells, not just their genetics, is a viable therapeutic strategy.
Mechanism
Leiomyosarcoma retains caldesmon (CALD1) from its smooth muscle lineage. Caldesmon stabilizes actin filaments by increasing persistence length from ~10um to ~17um, shifting the strain-stiffening onset of the actomyosin network to higher strains (gamma_c from ~15% to ~35%). ERK directly phosphorylates caldesmon at Ser789, releasing it from actin and lowering gamma_c. The cell invades ONLY when the phospho-CALD1 fraction exceeds a critical value that drops gamma_c below the local ECM strain.
The quantitative model: gamma_c(f) = gamma_c0 * (1 - f/f_max)^alpha, where f is the phospho-CALD1 fraction.
Critical insight: MEK inhibitors (trametinib) would raise the invasion threshold by reducing p-CALD1 -- repurposing existing cancer drugs for a novel mechanical target.
Supporting Evidence
- GROUNDED ERK phosphorylates caldesmon at Ser789 -- Hirano et al. 2004 J Biol Chem
- GROUNDED Caldesmon-actin stabilization -- Ishikawa et al. 2003, Hossain et al. 2003
- GROUNDED Actomyosin strain-stiffening -- Koenderink et al. 2009 PNAS
- GROUNDED MAPK activation in ~30% of LMS -- TCGA sarcoma 2017
- [NOVEL] p-CALD1 fraction determines gamma_c via power-law relationship
- [NOVEL] MEK inhibitors have anti-invasion activity through caldesmon re-activation
How to Test
Predictions: 1. p-CALD1(Ser789)/total CALD1 ratio correlates with invasion (R^2 > 0.5), while total CALD1 does NOT (R^2 < 0.2)
- Trametinib (10nM) reduces p-CALD1 by >50%, increases gamma_c by >40%, reduces invasion by >60%
- LMS patients receiving MEK inhibitor-containing regimens show longer metastasis-free survival (HR < 0.6)
Cross-Model Validation
Independent AssessmentIndependently assessed by GPT-5.4 Pro and Gemini 3.1 Pro for triangulation. Assessed independently by two external models for triangulation.
Other hypotheses in this cluster
Desmin Cage Compressive Stiffness Determines Nuclear Rupture Threshold: Quantitative Chromothripsis Accumulation Rate
PASSLosing a protein 'cage' around cancer cell nuclei may cause DNA to shatter, making tumors more aggressive over time.
MYH11 Paradoxical Self-Limiting Invasion Through Excessive Contractile Stress
CONDITIONALIn rare muscle cancers, too much cellular force may actually stop tumors from spreading — more power, less invasion.
Two-Component Rheological Barrier: Caldesmon + Calponin Synergistic Anti-Invasion Effect
CONDITIONALTwo muscle proteins may act as a tag-team force field that blocks cancer cells from spreading through tissue.
Stress Fiber Yielding Dynamics Set Pulsatile LMS Invasion Frequency: Laser Ablation Dissection
CONDITIONALCancer cells may invade surrounding tissue in rhythmic pulses timed by the slow snap-and-recover cycle of their internal scaffolding.
Related hypotheses
Adenosine-CXCL9 Turing Instability Generates Periodic Immune Hot/Cold Zones in Solid Tumors
PASSTumors may create immune hot and cold zones through the same math that gives zebras their stripes.
Variance-Component Decomposition of E. coli Adder — DnaA Counting Dominant at Fast Growth
CONDITIONALBacteria switch which internal clock controls their size depending on how fast they're growing.
Dual Saturation Index Competition Predicts LLPS vs. Crystallization Pathway Switching in Ionizable Drug ASD Dissolution
CONDITIONALEquations from volcano science could predict whether experimental drugs dissolve properly or crash out as useless crystals.
Can you test this?
This hypothesis needs real scientists to validate or invalidate it. Both outcomes advance science.